Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona

Abstract:
Flagship Facility Compliant with Worldwide Nanobiologics Regulatory Requirements

Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona

Los Angeles, CA | Posted on November 5th, 2009

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc. (NASDAQ:ABII), today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs. The new facility will manufacture ABRAXANE®, the first solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using Abraxis BioScience's proprietary nab® technology platform. The company now has multiple agreements in place for the development of novel, insoluble compounds using the nanobiologics technology employed at the Phoenix plant.

The facility will be the world's largest and most sophisticated protein nanobiologics manufacturing plant, with annual production capacity of over 10 million units, and the capability to expand to 20 million units, suitable for worldwide distribution. The site, formerly owned by Watson Pharmaceuticals, was purchased by Abraxis in July 2007. Abraxis has hired more than 100 former Watson employees, recruited additional staff from among the local skilled workforce, and will continue to recruit as the facility ramps up production.

"The outlook for Abraxis is immensely encouraging," said founder and Chairman Dr. Patrick Soon-Shiong. "As we continue to grow, these new premises in Phoenix will become the flagship manufacturing facility for our cutting edge technology."

State Attorney General Terry Goddard commented, "Arizona is proud to welcome Abraxis as a powerful new addition to our growing life sciences sector."

"This is great news for Phoenix," said Mayor Phil Gordon. "We are delighted that Abraxis has chosen our city for this state of the art nanotech manufacturing plant, bringing highly skilled jobs and a welcome boost for our economy."

State, city and business leaders attended today's ceremony to dedicate the new facility, including Attorney General Goddard and Mayor Phil Gordon.

####

About Abraxis BioScience
Abraxis Health, which will operate the Phoenix facility, is a division of Abraxis Bioscience Inc. Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

For more information, please click here

Contacts:
Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman, 310-883-1300

Copyright © Abraxis BioScience

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Jobs

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Participate in the development of Malaysia’s National Graphene Action Plan 2020 October 10th, 2016

Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016

SUNY Poly Welcomes DPS as the Global Engineering Firm Opens Its U.S. Advanced Technology Group Headquarters at Cutting-Edge ZEN Building November 20th, 2015

Investments/IPO's/Splits

Nanometrics Announces Participation in Upcoming Investor Conferences July 25th, 2018

Nanometrics to Participate in the 10th Annual CEO Investor Summit 2018: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2018 in San Francisco June 28th, 2018

180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018

Nanometrics Updates Time of Webcast at Stifel 2018 Cross Sector Insight Conference June 12th, 2018

Nanomedicine

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Announcements

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

Industrial

Graphene nanotubes outperform ammonium salts and carbon black in PU applications September 11th, 2018

Carbon in color: First-ever colored thin films of nanotubes created: A method developed at Aalto University, Finland, can produce large quantities of pristine single-walled carbon nanotubes in select shades of the rainbow; the secret is a fine-tuned fabrication process -- and a s August 29th, 2018

Connecting the (Nano) Dots: NIST Says Big-Picture Thinking Can Advance Nanoparticle Manufacturing August 22nd, 2018

A colossal breakthrough for topological spintronics: BiSb expands the potential of topological insulators for ultra-low-power electronic devices August 2nd, 2018

Nanobiotechnology

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 September 20th, 2018

NUS researchers invent new test kit for quick, accurate and low-cost screening of diseases: Test results are denoted by a color change and could be further analyzed by a smartphone app, making it attractive as a point-of-care diagnostic device September 19th, 2018

Researchers develop microbubble scrubber to destroy dangerous biofilms September 19th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project